Azenosertib in combination with chemotherapy is evaluated in patients with platinum-resistant ovarian cancer. Credit: Chinnapong / Shutterstock.

Zentalis Pharmaceuticals has reported positive data from a Phase Ib trial evaluating its WEE1 inhibitor, azenosertib combined with chemotherapy in patients with platinum-resistant ovarian cancer.

The trial enrolled a total of 115 patients across all chemotherapy combination groups.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Azenosertib was well tolerated in combination with multiple chemotherapy types and demonstrated significant clinical activity.

Improvements were observed in objective response rates (ORRs) and median progression-free survival (mPFS) in all patients.

Patients with Cyclin E1+ tumours, a subgroup having a poor prognosis and refractory to chemotherapy, benefited most in chemotherapy combination arms.

Azenosertib plus paclitaxel demonstrated the highest ORR of 50% followed by an ORR of 38.5% for azenosertib plus gemcitabine in all dosing schedules.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

ORR of 35.7% was also observed when patients received azenosertib plus carboplatin and 19.4% in azenosertib plus PLD.

All azenosertib intermittent dosing groups showed Grade ≥3 treatment-related adverse events including neutropenia, fatigue, thrombocytopenia and anaemia.

Zentalis Pharmaceuticals CEO Kimberly Blackwell said: “We are very encouraged by our robust chemotherapy combination data, particularly the strong efficacy and tolerability results when dosing azenosertib intermittently.

“These data provide a compelling rationale to advance azenosertib into a registrational study in combination with either carboplatin or paclitaxel in Cyclin E1+ ovarian cancer.”

A recommended Phase II dose was also determined for each of the azenosertib combinations with carboplatin, paclitaxel, and PLD.

The company also plans to start a Phase III study comparing azenosertib dosed intermittently along with either paclitaxel or carboplatin in Cyclin E1+ platinum-sensitive ovarian cancer patients.

The study is anticipated to start in the first quarter of next year.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact